Cardiol Therapeutics Inc. – NASDAQ:CRDL
Cardiol Therapeutics stock price today
$1.14
-0.17
-12.98%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 8 hours
Cardiol Therapeutics stock price monthly change
-38.50%
month
Cardiol Therapeutics stock price quarterly change
-38.50%
quarter
Cardiol Therapeutics stock price yearly change
+57.60%
year
Cardiol Therapeutics key metrics
Market Cap | 104.04M |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -0.47 |
Revenue | N/A |
EBITDA | -29.52M |
Income | -30.21M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCardiol Therapeutics stock price history
Cardiol Therapeutics stock forecast
Cardiol Therapeutics financial statements
| Jun 2023 | 0 | -7.47M | |
|---|---|---|---|
| Sep 2023 | 0 | -5.93M | |
| Dec 2023 | 0 | -7.63M | |
| Mar 2024 | 0 | -9.17M |
| Sep 2025 | 0 | -6.38M | |
|---|---|---|---|
| Dec 2025 | 0 | -5.39M | |
| Mar 2026 | 0 | -5.39M | |
| Jun 2026 | 0 | -6.38M |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 47169272 | 8.41M | 17.85% |
|---|---|---|---|
| Sep 2023 | 43053024 | 8.18M | 19.01% |
| Dec 2023 | 36700508 | 8.45M | 23.04% |
| Mar 2024 | 31126280 | 11.06M | 35.56% |
| Jun 2023 | -5.35M | -3.89K | -13.84K |
|---|---|---|---|
| Sep 2023 | -3.41M | -5.57K | -13.84K |
| Dec 2023 | -6.46M | -10.70K | -13.84K |
| Mar 2024 | -6.92M | -3.46K | 76.35K |
Cardiol Therapeutics alternative data
| Mar 2024 | 22 |
|---|---|
| Apr 2024 | 22 |
| May 2024 | 22 |
| Jun 2024 | 22 |
| Jul 2024 | 22 |
Cardiol Therapeutics other data
10.87%
-4.74%
of CRDL is owned by hedge funds
6.79M
+47.15K
shares is hold by hedge funds
-
What's the price of Cardiol Therapeutics stock today?
One share of Cardiol Therapeutics stock can currently be purchased for approximately $1.14.
-
When is Cardiol Therapeutics's next earnings date?
Unfortunately, Cardiol Therapeutics's (CRDL) next earnings date is currently unknown.
-
Does Cardiol Therapeutics pay dividends?
No, Cardiol Therapeutics does not pay dividends.
-
How much money does Cardiol Therapeutics make?
Cardiol Therapeutics has a market capitalization of 104.04M.
-
What is Cardiol Therapeutics's stock symbol?
Cardiol Therapeutics Inc. is traded on the NASDAQ under the ticker symbol "CRDL".
-
What is Cardiol Therapeutics's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
-
How do i buy shares of Cardiol Therapeutics?
Shares of Cardiol Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Cardiol Therapeutics have?
As Jul 2024, Cardiol Therapeutics employs 22 workers.
-
When Cardiol Therapeutics went public?
Cardiol Therapeutics Inc. is publicly traded company for more then 6 years since IPO on 15 Jan 2019.
-
What is Cardiol Therapeutics's official website?
The official website for Cardiol Therapeutics is cardiolrx.com.
-
Where are Cardiol Therapeutics's headquarters?
Cardiol Therapeutics is headquartered at 2265 Upper Middle Road East, Oakville, ON.
-
How can i contact Cardiol Therapeutics?
Cardiol Therapeutics's mailing address is 2265 Upper Middle Road East, Oakville, ON and company can be reached via phone at 289 910 0850.
Cardiol Therapeutics company profile:
Cardiol Therapeutics Inc.
cardiolrx.comExchange:
NASDAQ
Full time employees:
22
Industry:
Drug Manufacturers - Specialty & Generic
Sector:
Healthcare
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
2265 Upper Middle Road East
Oakville, ON L6H 0G5
Oakville, ON L6H 0G5
CIK: 0001702123
ISIN: CA14161Y2006
CUSIP: 14161Y200
